JUL 10, 2018 8:45 PM PDT

New Potential Inhibitor Target for Mantle Cell Lymphoma

WRITTEN BY: Mauri Brueggeman

Mantle Cell Lymphoma (MCL) is a rare form of non-Hodgkin’s Lymphoma (NHL) and is so named because of the cells involved.  The mantle is part of follicular zones which surround germinal centers within each lymph node.  The mantle cells become mutagenic and as the mantle cell population grows, the remainder of the lymph cells.  The disease primarily involves the lymph nodes and less often, in about 25% of cases, in the blood or bone marrow.  MCL is usually aggressive.  The morphology of MCL is very similar to Chronic Lymphocytic Leukemia; nuclear irregularities in the cell can be more prominent but are often indistinguishable from CLL cells.  There are molecular techniques that can be used to diagnose MCL including evaluating cell markers like B-cell antigens CD19, CD20 & CD22 and using fluorescence in-site hybridization (FISH) to characterize the present of a translocation between chromosome 11 and chromosome 14.  In 90% of cases of MCL, a protein called cyclin D1 is also present.  Clinicians use these tests and the evaluation of blood levels of lactate dehydrogenase (LDH) and beta-2 microglobulin to determine aggressiveness and guide therapeutic intervention.  The challenge is that while some patients diagnosed with MCL are young and can undergo chemotherapy and a bone marrow transplant, the larger majority have disease identified in their later years at age 68 or older.  There is a need for additional alternative treatments.  

One group of researchers published an article in Oncotarget last month outlining a novel therapeutic option for targeting MCL cells.  The gene product of BMI-1 is required for the growth of MCL cells and is found to be upregulated in MCL.  A selective inhibitor, called PTC596, has been reported to inhibit BMI-1 expression in these cells.  PTC596 initiated apoptosis in MCL cells. 

BMI-1 is a proto-oncogene and polycomb ring finger protein that plays a role in chromatin remodeling and epigenetic labeling processes for regulating embryonic development and self-renewal in stem cells.  It is also protein know to participate in DNA damage repair.  According to the literature published on BMI-1, its divergent expression can also mean resistance to chemotherapy.  The gene is found on chromosome 10 at 10p12.2 and the resultant protein has 326 amino acids. 

The Federal Drug Administration in the US approved acalabrutinib last October for the treatment of adults with MCL but those patients need to have been treated with at least one prior therapy.  This drug was approved using the FDA’s accelerated approval process because there has been such a need for treatment for this very aggressive form of cancer.  Another treatment approach is the use of ibrutinib, which binds to Bruton’s tyrosine kinase (BTK).  This drug has been helpful in the treatment of CLL and can reduce the tumor burden in combination with other therapies.

Sources: Oncotarget, Lymphoma Research Foundation, Therapeutic Advances in Hematology, GeneCardsSuite, FDA,

About the Author
  • Mauri S. Brueggeman is a Medical Laboratory Scientist and Educator with a background in Cytogenetics and a Masters in Education from the University of Minnesota. She has worked in the clinical laboratory, taught at the University of Minnesota, and been in post secondary healthcare education administration. She is passionate about advances and leadership in science, medicine, and education.
You May Also Like
SEP 25, 2020
Clinical & Molecular DX
Ray of Hope: Rare Cancer Biomarker Discovered
SEP 25, 2020
Ray of Hope: Rare Cancer Biomarker Discovered
Biliary tract cancer, or BTC, isn’t as talked about as breast or prostate cancers, probably because its incidence ...
OCT 12, 2020
Drug Discovery & Development
Researchers Solve Key Problem for Cancer Immunotherapy
OCT 12, 2020
Researchers Solve Key Problem for Cancer Immunotherapy
Cancer immunotherapies are becoming increasingly promising as a standard-of-care treatment. However, despite their promi ...
OCT 20, 2020
Clinical & Molecular DX
Non-coding RNA As A Barometer For Liver Health
OCT 20, 2020
Non-coding RNA As A Barometer For Liver Health
October is liver cancer awareness month — a month dedicated to educating people about the risk factors and prevent ...
NOV 03, 2020
Genetics & Genomics
One Eight Cancer Patients Also Carry Inherited Genetic Mutations
NOV 03, 2020
One Eight Cancer Patients Also Carry Inherited Genetic Mutations
Genetic sequencing technologies have rapidly advanced, reducing the time required to sequence the entire human genome fr ...
NOV 18, 2020
Cancer
Could Targeting the Proteasome be Effective Against Cancer?
NOV 18, 2020
Could Targeting the Proteasome be Effective Against Cancer?
One of the trickiest things about anti-cancer drug design is targeting. Today, most drugs on the market target critical ...
NOV 13, 2020
Cancer
Predictive model assesses risk of adverse side effects for chemotherapy patients
NOV 13, 2020
Predictive model assesses risk of adverse side effects for chemotherapy patients
New research published in npj Systems Biology and Applications showcases a model capable of predicting which patien ...
Loading Comments...